KTTA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 16.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Pasithea Therapeutics Insider Trading History Chart

Pasithea Therapeutics Share Price & Price History

^$5.05

▲ +0.39 (8.37%)

As of 07/26/2024 01:00 AM ET

Days: 30 | 90 | 365

This student turned $1,300 into $45,000 in just 4 Months!

From Monument Traders Alliance | Ad

With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.

See here to see the full details.

Pasithea Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/2/2023	Lawrence Steinman	Director	Buy	1,500	$8.60	$12,900.00	66,358
10/17/2022	David Delaney	Major Shareholder	Buy	50	$22.20	$1,110.00	11,376
9/28/2022	Eric Shahinian	Major Shareholder	Buy	2,882	$23.80	$68,591.60	89,085
8/29/2022	Eric Shahinian	Major Shareholder	Buy	250	$23.40	$5,850.00	80,866
8/19/2022	Avi Geller	Major Shareholder	Buy	2,732	$26.00	$71,032.00	2,732
8/17/2022	Eric Shahinian	Major Shareholder	Buy	7,788	$24.20	$188,469.60	80,566

625,000% Gain

From Crypto Swap Profits | Ad

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

SEC Filings (Institutional Ownership Changes) for Pasithea Therapeutics (NASDAQ:KTTA)

23.92% of Pasithea Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Pasithea Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/10/2023	K2 Principal Fund L.P.	282,437	$0.18M	0.0%	-42.6%	0.966%
5/12/2022	Mark Sheptoff Financial Planning LLC	48,000	$62K	0.0%	N/A	0.210%
2/11/2022	K2 Principal Fund L.P.	550,000	$0.97M	0.1%	N/A	4.164%
11/16/2021	Two Sigma Securities LLC	10,440	$32K	0.0%	N/A	0.080%

Data available starting January 2016

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Today's Range

Now: $5.05

$5.02

$5.16

50 Day Range

MA: $5.59

$4.66

$6.65

52 Week Range

Now: $5.05

$4.46

$17.40

Volume

2,752 shs

Average Volume

7,240 shs

Market Capitalization

$5.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Who are the company insiders with the largest holdings of Pasithea Therapeutics?: Pasithea Therapeutics' top insider investors include:
Eric Shahinian (Major Shareholder)
Lawrence Steinman (Director)
David Delaney (Major Shareholder)
Avi Geller (Major Shareholder)
Learn More about top insider investors at Pasithea Therapeutics.